BMY Technical Analysis
As of date:2/14/2020
BMY stock price:66.38
BMY 50 DMA:64.17
BMY 200 DMA:52.41
BMY MACD (200-50):-11.76
BMY RSI:63.48
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)63.48
Extremely
Oversold

Also see:
BMY Market Cap History
BMY Shares Outstanding History
BMY YTD Return

Quotes delayed 20 minutes
Get Free SEC filing alerts for BMY:
BMY SEC Filing Email Alerts ServiceExternal link

SMAWF Makes Notable Cross Below Critical Moving Average
Friday, February 14, 4:38 PM


EIGR Makes Notable Cross Below Critical Moving Average
Friday, February 14, 4:37 PM


PACW Makes Bullish Cross Above Critical Moving Average
Friday, February 14, 4:32 PM


MLCO Crosses Below Key Moving Average Level
Friday, February 14, 4:32 PM


FLOW Makes Notable Cross Below Critical Moving Average
Friday, February 14, 4:32 PM


IBERIABANK (IBKC) Shares Cross Below 200 DMA
Friday, February 14, 4:28 PM


Notable Two Hundred Day Moving Average Cross - FBNC
Friday, February 14, 4:28 PM


Unity Bancorp Breaks Below 200-Day Moving Average - Notable for UNTY
Friday, February 14, 4:28 PM


Westlake Chemical (WLK) Shares Cross Below 200 DMA
Friday, February 14, 4:08 PM


Banco Santander (Spain) Breaks Below 200-Day Moving Average - Notable for SAN
Friday, February 14, 4:08 PM


SRLP Crosses Critical Technical Indicator
Friday, February 14, 3:57 PM


CNX Midstream Partners (CNXM) Shares Enter Oversold Territory
Friday, February 14, 3:57 PM


Bullish Two Hundred Day Moving Average Cross - SJI
Friday, February 14, 3:57 PM


Notable Two Hundred Day Moving Average Cross - ASGN
Friday, February 14, 3:57 PM


Rapid7 Breaks Below 200-Day Moving Average - Notable for RPD
Friday, February 14, 11:40 AM


More Technical Analysis News

BMY Technical AnalysisBMY RSI
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Co.'s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Co. manufactures products in the U.S., Puerto Rico and in four foreign countries. Co. has products in the following therapeutic classes: oncology; cardiovascular; and immunoscience. Co.'s products include: Opdivo; Eliquis; Orencia; Sprycel; Yervoy; Empliciti; Baraclude; the Reyataz Franchise; the Sustiva Franchise; and the Hepatitis C Franchise.

When researching a stock like Bristol-Myers Squibb, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from BMY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for BMY stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
BMY DMABMY MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Bristol-Myers Squibb (BMY) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

BSX Technical Analysis
CAH Technical Analysis
CELG Technical Analysis
CNC Technical Analysis
COO Technical Analysis
DGX Technical Analysis
DHR Technical Analysis
DVA Technical Analysis
EW Technical Analysis
GILD Technical Analysis
More Healthcare companies »

 

BMY Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2020, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.